Vaccines growth offsets Advair generic pain for GSK
25-07-2019
Swiss court mulls extradition of Chinese researcher accused of GSK trade secrets theft
10-07-2019
Willy Barton / Shutterstock.com
Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline (GSK).
In an announcement yesterday, August 27, Ionis said GSK had decided to agree on licensing the programme following positive phase two results.
Chronic hepatitis B is a viral infection of the liver that can lead to significant and potentially fatal health conditions such as liver failure and liver cancer.
As part of the agreement, Ionis is eligible to receive milestone payments of up to $262 million, including a $25 million licence fee, as well as tiered royalties “in the low double digits” on net sales.
According to the press release, GSK is now responsible or all development, regulatory and commercialisation activities and costs.
Brett Monia, chief operating officer at Ionis, said the antisense technology “can potentially deliver a transformative medicine” for sufferers.
He added: "We believe GSK's expertise in infectious diseases makes them the ideal partner to help address this high unmet need."
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GlaxoSmithKline, Ionis Pharmaceuticals, antisense, chronic hepatitis B, licensing, liver cancer, liver disease, virus
